77 Updated Efficacy of Mutant-Selective PI3Kα Inhibitor Zovegalisib (RLY-2608) in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial
BySarah L. Sammons,Cristina Saura,Antoine Italiano,Alison Schram, MD,Pablo Tolosa,Anne F. Schott, MD,Á. Guerrero-Zotano,Santiago Ponce-Aix,Rita Nanda, MD,Kari B. Wisinski, MD,Jennifer Segar,Mei Wei,Jia (Jenny) Liu,Alexander Spira, MD, PhD, FACP, FASCO,Julia E. McGuinness, MD,Jordi Rodón,Cynthia X. Ma, MD, PhD,Milana Bergamino,Giuseppe Curigliano,Andreas Varkaris
Zovegalisib plus fulvestrant demonstrated an objective response rate of 38.7% and a median progression-free survival of 10.3 months in PIK3CA-mutant HR+/HER2– advanced breast cancer in the ReDiscover trial.
